Answers are grounded in this paper and cite their sources.
Observational study evaluates adverse drug reactions in oncology, highlighting the need for pharmacovigilance.
Pharmacotherapeutic monitoring of adverse drug reactions (ADRs), particularly in oncology, is essential to ensure patient safety and treatment adherence. In this context, the present study aimed to evaluate the frequency of ADRs associated with the infusion of antineoplastic drugs in outpatient oncology clinics through passive and active pharmacovigilance. The current observational, retrospective study adopted a quantitative approach and included all patients who experienced infusion-related ADRs between July 2020 and July 2024. Data were collected from institutional pharmacovigilance records and electronic medical charts. A total of 1,073 ADR events were reported, with a higher frequency observed in treatment protocols containing taxanes and platinum-based agents. Paclitaxel accounted for 23.02% of ADRs (n = 247), followed by oxaliplatin (20.96%; n = 225) and docetaxel (10.44%; n = 112). The protocols most frequently associated with ADRs were paclitaxel 175 mg/m2 (dose-dense), folinic acid, fluorouracil and oxaliplatin (FOLFOX 6 modified), and modified FOLFOX 6 plus bevacizumab. The ADRs were more frequent among patients aged 61 to 70 years, with a predominance of female subjects (73%). Most reactions were described in package inserts or the literature (99%), occurred during the first infusion (72%), were classified as grade 2 (moderate) according to the Common Terminology Criteria for Adverse Events (CTCAE; 96%), and enabled treatment completion after appropriate management (85%). Pharmaceutical interventions resulted in changes to subsequent treatment cycles in 28% (296 patients) of the cases. The current study highlights the importance of pharmacovigilance and pharmacotherapeutic monitoring in oncology, contributing to safer medication use, improved management of adverse reactions, and greater patient adherence to antineoplastic treatment.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: